Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT04435691	Phase Ib/II	Azacitidine + Hu5F9-G4 + Venetoclax	Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia	Active, not recruiting	USA	0
NCT03144804	Phase II	Lamivudine	A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer	Completed	USA	0
NCT04155840	Phase II	Bendamustine + Copanlisib + Rituximab	Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Terminated	USA	0
NCT03661307	Phase Ib/II	Decitabine + Quizartinib + Venetoclax	Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome	Recruiting	USA	0
NCT04190550	Phase I	Cytarabine + Idarubicin + KRT-232	Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia	Active, not recruiting	USA	0
NCT02518555	Phase II	Ibrutinib	Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Active, not recruiting	USA	0
NCT05275439	Phase I	Azacitidine + SL-172154 + Venetoclax Azacitidine + SL-172154 SL-172154	Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML	Recruiting	USA \| GBR \| CAN	0
NCT04778397	Phase III	Cytarabine + Idarubicin Azacitidine + Venetoclax Azacitidine + Hu5F9-G4 Cytarabine + Daunorubicin	Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated (ENHANCE-2)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	5
NCT05932667	Phase II	Fulvestrant + Milademetan	Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer (DEMETER)	Not yet recruiting	FRA	0
NCT05338346	Phase I	ATG-018	A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM)	Recruiting	AUS	0
NCT01097278	Phase 0	Cholecalciferol	S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer	Completed	USA	0
NCT04049539	Phase II	CPX-351	Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction	Recruiting	USA	0
NCT05605509	Phase II	Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306	RP-6306 in Patients With Advanced Cancer	Recruiting	CAN	0
NCT03654716	Phase I	ALRN-6924 + Cytarabine ALRN-6924	Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer	Completed	USA	0
NCT02842125	Phase I	Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab	Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer	Terminated	USA	0
NCT04214860	Phase I	APR-246 + Azacitidine + Venetoclax	APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies	Completed	USA	0
NCT05008055	Phase II	Capivasertib	Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)	Active, not recruiting	USA \| GBR \| FRA \| ESP \| CAN	2
NCT05332483	Phase I	Megestrol acetate	Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer (MA-EEC)	Recruiting	CAN	0
NCT04293094	Phase I	AMG 650	Study of AMG 650 in Adult Participants With Advanced Solid Tumors	Completed	USA \| ITA \| ESP \| CAN \| BEL \| AUS	1
NCT04510584	Phase II	Atezolizumab + Bevacizumab	Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer	Withdrawn	CAN	0
NCT02629809	Phase II	Cyclophosphamide + Fludarabine + Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab Ibrutinib	Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia	Active, not recruiting	USA	0
NCT05218499	Phase II	BI 907828 Doxorubicin	Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	14
NCT03913026	Phase II	ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa	UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia	Recruiting	CAN	0
NCT02343172	Phase Ib/II	Ribociclib + Siremadlin	Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma	Completed	FRA \| ESP \| DEU \| CAN	2
NCT03668340	Phase II	Adavosertib	AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	Recruiting	USA	0
NCT04169737	Phase II	Acalabrutinib + Obinutuzumab + Venetoclax	Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Recruiting	USA	0
NCT04660045	Phase II	Acalabrutinib	Early Intervention With Acalabrutinib in Patients With High Risk CLL	Withdrawn	USA	0
NCT04159155	Phase II	Carboplatin + Cisplatin + Paclitaxel Carboplatin + Niraparib + Paclitaxel Carboplatin + Paclitaxel	A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer (CAN-STAMP)	Suspended	CAN	0
NCT03360721	Phase II	Abiraterone + Apalutamide + Prednisone	Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients	Active, not recruiting	USA	0
NCT03072043	Phase Ib/II	APR-246 + Azacitidine	Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms	Completed	USA	0
NCT03128879	Phase II	Acalabrutinib + Venetoclax Ibrutinib + Venetoclax	Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL	Recruiting	USA	0
NCT02299141	Phase I	Nintedanib	Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03063203	Phase II	Decitabine	Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia	Terminated	USA	0
NCT04113616	Phase Ib/II	KRT-232 Decitabine + KRT-232 Cytarabine + KRT-232	An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	4
NCT04708054	Phase II	Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax	Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS	Recruiting	USA	0
NCT04634877	Phase III	Carboplatin + Paclitaxel Cisplatin + Paclitaxel Carboplatin + Docetaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Docetaxel + Pembrolizumab Cisplatin + Docetaxel Carboplatin + Docetaxel + Pembrolizumab	Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT	19
NCT01027416	Phase I	Tamoxifen	Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients	Completed	USA	0
NCT05611931	Phase III	Selinexor	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC)	Recruiting	USA \| ESP \| BEL	2
NCT02642042	Phase II	Docetaxel + Trametinib	Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT05622058	Phase I	ALRN-6924 + Cyclophosphamide + Docetaxel + Doxorubicin	A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer	Terminated	USA	3
NCT03449381	Phase I	BI 907828	This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)	Recruiting	USA \| ESP \| DEU \| CAN \| BEL	5
NCT04659616	Phase I	Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib	Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia	Recruiting	USA	0
NCT05396859	Phase I	Decitabine and Cedazuridine + Entrectinib	Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia	Recruiting	USA	0
NCT03732352	Phase II	Osimertinib	18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma	Active, not recruiting	USA	0
NCT03365661	Phase II	ALT-803	QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML	Withdrawn	USA	0
NCT04722172	Phase II	Acalabrutinib + Obinutuzumab	A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL	Active, not recruiting	USA	0
NCT04419389	Phase Ib/II	Acalabrutinib + APR-246 APR-246 + Rituximab + Venetoclax	APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)	Terminated	USA	0
NCT01339871	Phase I	Vorinostat Pazopanib	Phase I Study of Pazopanib and Vorinostat	Completed	USA	0
NCT04146038	Phase II	Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax	Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease	Completed	USA	0
NCT01357161	Phase II	Carboplatin Adavosertib Paclitaxel	A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)	Completed		0
NCT03567642	Phase I	Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib	A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers	Recruiting	USA	0
NCT02193152	Phase I	Pazopanib	Pazopanib in Molecularly Selected Patients With Advanced NSCLC	Terminated	USA	0
NCT05512377	Phase II	BI 907828	Brightline-2: A Study to Test Whether BI 907828 Helps People With Cancer in the Biliary Tract or Pancreas	Recruiting	USA \| FRA \| ESP \| DEU \| BEL \| AUT \| AUS	6
NCT03931291	Phase II	APR-246 + Azacitidine	APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant	Completed	USA	0
NCT04010968	Phase II	Ibrutinib + Venetoclax Cyclophosphamide + Fludarabine + Rituximab	Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia (ERADIC)	Active, not recruiting	FRA	0
NCT04022876	Phase I	ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium	A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)	Terminated	USA \| ITA \| ESP \| DEU	3
NCT04277442	Phase I	Decitabine + Nivolumab + Venetoclax	Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia	Active, not recruiting	USA	0
NCT03634228	Phase Ib/II	Cytarabine + Milademetan Cytarabine + Milademetan + Venetoclax	Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia	Terminated	USA	0
NCT04388852	Phase I	DS-3201b + Ipilimumab	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	Recruiting	USA	0
NCT05431582	Phase I	Bevacizumab + Pembrolizumab + ZN-c3 Bevacizumab + ZN-c3	Phase I Study of ZN-c3 and Bevacizumab +/- Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors	Withdrawn		0
NCT03047993	Phase Ib/II	Azacitidine + Telaglenastat	Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome	Completed	USA	0
NCT05180695	Phase Ib/II	Pazopanib + Siremadlin	HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas (AMPHISARC)	Recruiting	FRA	0
NCT04908228	Phase II	Ibrutinib + Obinutuzumab	Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naive Patients With CLL	Recruiting	ITA	0
NCT03613532	Phase I	Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine	Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	Recruiting	USA	0
NCT05156268	Phase II	Olaparib + Pembrolizumab	A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma	Recruiting	USA	0
NCT05155709	Phase Ib/II	Azacitidine + Siremadlin + Venetoclax	A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.	Recruiting	USA \| ITA \| ESP \| AUS	6
NCT03734198	Phase II	Daratumumab + Ibrutinib	Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53)	Active, not recruiting	FRA	0
NCT04734990	Phase Ib/II	Azacitidine + Seclidemstat	Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia	Active, not recruiting	USA	0
NCT05027867	Phase II	KRT-232	KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer	Terminated	USA \| FRA \| ESP \| DEU \| AUS	2
NCT03745716	Phase III	APR-246 + Azacitidine Azacitidine	APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)	Completed	USA \| FRA	0
NCT05495464	Phase I	Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab	A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma	Recruiting	USA	0
NCT04783415	Phase II	Acalabrutinib + Ublituximab + Umbralisib	Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma	Active, not recruiting	USA	0
NCT04402073	Phase II	Cisplatin + Lomustine + Vincristine Sulfate Cisplatin + Lomustine + Sonidegib + Vincristine Sulfate	Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)	Recruiting	DEU \| AUS	1
NCT02576444	Phase II	Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib	OLAParib COmbinations (OLAPCO)	Terminated	USA	0
NCT05405309	Phase Ib/II	Olaparib + RP-3500	RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL)	Suspended	USA	0
NCT02301156	Phase III	Ibrutinib + Ublituximab Ibrutinib	Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)	Completed	USA	1
NCT02275039	Phase I	MVAp53 Gemcitabine	p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer	Completed	USA	0
NCT02042989	Phase I	Ixazomib + Vorinostat	MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies	Completed	USA	0
NCT02433626	Phase I	COTI-2 Cisplatin + COTI-2	Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101)	Unknown status	USA	0
NCT03781986	Phase Ib/II	APG-115	APG-115 in Salivary Gland Cancer Trial	Recruiting	USA	0
NCT04285567	Phase III	Obinutuzumab + Venetoclax Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab	A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)	Active, not recruiting	USA \| ITA \| FRA \| ESP \| AUS	0
NCT05376800	Phase I	BI 907828	A Study to Determine How BI 907828 is Taken up in the Tumor and to Determine the Highest Dose of BI 907828 That Could be Tolerated in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma	Recruiting	USA	0
NCT04412629	Phase II	Cabozantinib	Cabozantinib in High Grade Neuroendocrine Neoplasms	Recruiting	USA	0
NCT01760525	Phase I	CGM097	A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors	Completed	USA \| FRA \| DEU	2
NCT02098343	Phase Ib/II	Carboplatin + Doxorubicin APR-246 + Carboplatin + Doxorubicin	p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	Completed	USA \| GBR \| FRA \| ESP \| DEU \| BEL	2
NCT03462719	Phase III	Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax	A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)	Active, not recruiting	USA \| GBR \| FRA \| ESP \| CAN \| BEL	8
NCT03836261	Phase III	Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax	Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUT \| AUS	20
NCT04485260	Phase Ib/II	KRT-232 + Ruxolitinib	An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib	Recruiting	USA \| ITA \| FRA \| ESP \| DEU \| AUS	3
NCT03844815	Phase I	Decitabine + Venetoclax	Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia	Recruiting	USA	0
NCT04493138	Phase Ib/II	Azacitidine + Quizartinib	Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations	Recruiting	USA	0
NCT03383575	Phase II	Azacitidine + Enasidenib Enasidenib	Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome	Recruiting	USA	0
NCT04592237	Phase II	Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	Recruiting	USA	0
NCT03932643	Phase I	ONC201	ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant	Recruiting	USA	0
NCT05624554	Phase III	Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab ARQ 531	A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)	Recruiting	AUS	14
NCT02007044	Phase II	Ibrutinib Ibrutinib + Rituximab	Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	Active, not recruiting	USA	0
NCT03945721	Phase I	Niraparib	A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients (UNITY)	Recruiting	USA	0
NCT05748171	Phase II	Asparaginase + Dexamethasone + Mitoxantrone + Vincristine Sulfate Inotuzumab ozogamicin	A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL	Recruiting	ITA \| FRA \| ESP \| DEU \| BEL	8
NCT02432963	Phase I	MVAp53 + Pembrolizumab	Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy	Active, not recruiting	USA	0
NCT03204188	Phase II	Fludarabine + Ibrutinib + Pembrolizumab	Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Active, not recruiting	USA	0
NCT03940352	Phase I	Siremadlin + Venetoclax Sabatolimab + Siremadlin	HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)	Active, not recruiting	USA \| ITA \| ESP \| DEU \| AUS	2
NCT03641313	Phase II	Berzosertib + Irinotecan	Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	Active, not recruiting	USA	0
NCT05797831	Phase II	KRT-232	Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer	Recruiting	USA	1
NCT02143635	Phase I	Siremadlin	Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt	Completed	USA \| FRA \| ESP \| DEU	4
NCT03107780	Phase I	KRT-232	Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer	Recruiting	USA	0
NCT02264613	Phase Ib/II	ALRN-6924	Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors	Completed	USA	0
NCT03787602	Phase Ib/II	Avelumab + KRT-232 KRT-232	Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma	Recruiting	USA \| ITA \| FRA \| ESP \| DEU \| CAN \| AUS	3
NCT03725436	Phase I	ALRN-6924 + Paclitaxel	ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors	Active, not recruiting	USA	0
NCT03560882	Phase I	Atorvastatin	A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies	Recruiting	USA	0
NCT04502394	Phase Ib/II	Acalabrutinib + KRT-232	Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL	Recruiting	USA \| ITA \| GBR \| FRA \| BEL \| AUS	5
NCT04835584	Phase Ib/II	Dasatinib + KRT-232 KRT-232 + Nilotinib	KRT-232 and TKI Study in Chronic Myeloid Leukemia	Recruiting	USA \| ITA \| FRA \| ESP \| CAN	3
NCT04116541	Phase II	Alectinib Cabozantinib Ribociclib + Siremadlin	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)	Recruiting	FRA	0
NCT02909972	Phase I	ALRN-6924 + Cytarabine ALRN-6924	Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	Completed	USA	0
NCT03975387	Phase Ib/II	ASTX295	Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53	Active, not recruiting	USA	0
NCT04669067	Phase Ib/II	KRT-232 + TL-895	TL-895 and KRT-232 Study in Acute Myeloid Leukemia	Active, not recruiting	USA \| ITA \| FRA \| ESP \| DEU \| AUT \| AUS	1
NCT03041688	Phase I	Decitabine + KRT-232	Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine in Patients With Acute Myeloid Leukemia	Recruiting	USA	0
NCT03964233	Phase I	BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab BI 907828	A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With Ezabenlimab With or Without BI 754111	Recruiting	USA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	4
NCT03714958	Phase I	Siremadlin + Trametinib	Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD)	Completed	FRA	0
NCT01914900	Phase II	Cisplatin + Docetaxel + Fluorouracil	Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer	Completed	ITA	0
NCT01042535	Phase Ib/II	Ad.p53-DC vaccine + Indoximod	Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer	Completed	USA	0
NCT03363867	Phase II	Atezolizumab + Bevacizumab + Cobimetinib	BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON)	Active, not recruiting	AUS	0
NCT02612285	Phase II	SNX-5422	Study of SNX-5422 in TP53 Null Cancers	Terminated	USA	0
NCT05691465	Phase II	lutetium Lu 177 dotatate	Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells	Recruiting	USA	0
NCT04585750	Phase Ib/II	PC14586	The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)	Recruiting	USA	0
NCT05877599	Phase I	NT-175	A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation	Recruiting	USA	0

Gene Detail

Contact

Filtering

Sorting